Compare SURG & ITRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SURG | ITRM |
|---|---|---|
| Founded | 2006 | 2015 |
| Country | United States | Ireland |
| Employees | 20 | N/A |
| Industry | Advertising | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 20.3M | 24.3M |
| IPO Year | N/A | 2018 |
| Metric | SURG | ITRM |
|---|---|---|
| Price | $0.72 | $0.03 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 2 |
| Target Price | ★ $9.75 | $9.00 |
| AVG Volume (30 Days) | 89.1K | ★ 23.7M |
| Earning Date | 05-12-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 57.43 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $3.78 | N/A |
| Revenue Next Year | $113.46 | $947.65 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.69 | $0.03 |
| 52 Week High | $3.47 | $1.42 |
| Indicator | SURG | ITRM |
|---|---|---|
| Relative Strength Index (RSI) | 34.51 | 26.10 |
| Support Level | N/A | N/A |
| Resistance Level | $0.95 | $0.39 |
| Average True Range (ATR) | 0.07 | 0.02 |
| MACD | -0.00 | -0.01 |
| Stochastic Oscillator | 9.69 | 3.34 |
Surgepays Inc is a fintech company focused on the underbanked community. It provides services to financial technology, telecommunications, and digital media companies. Its operating segment includes Mobile Virtual Network Operators that provide mobile broadband (internet connectivity), voice and SMS text messaging to both subsidized and direct retail prepaid customers through SurgePhone Wireless, LLC and Torch Wireless, LLC; Comprehensive Platform Services provide financial technology and a wireless top-up platform to independently owned convenience stores throughout the country; and Others. It generates the majority of its revenue from the Mobile Virtual Network Operators segment.
Iterum Therapeutics PLC is a pharmaceutical company dedicated to maximizing the commercial potential of Orlynvah, an oral-branded penem available in the United States and potentially the first and only oral and intravenous (IV) branded penem available globally. Its product Orlynvah has the potential to be a treatment for complicated urinary tract infections caused by the designated microorganisms, without the presence of known toxicities of some other antibiotics. The company operates in a single business segment, which is the development and commercialization of treatments for drug-resistant bacterial infections.